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ABSTRACT
Expression of the complete HIV-1 genome depends
on the appropriate processing of viral RNA. Altering
the balance of viral RNA processing impairs replication of the virus. In this report, we characterize two
small molecule modulators of HIV-1 RNA processing,
8-azaguanine and 2-(2-(5-nitro-2-thienyl)vinyl)quinoline (5350150), which function by distinct mechanisms to suppress viral gene expression. Although
only 8-Azaguanine dramatically decreased accumulation of HIV-1 unspliced and singly spliced RNAs and
altered splice site usage, both compounds blocked
Gag and Env expression without affecting production
of Tat (p16) and Rev regulatory proteins. Subsequent
analyses suggest that these compounds affect Revmediated RNA transport by different mechanisms.
Both compounds induced cytoplasmic accumulation
of Rev, suggesting that they function, in part, by impairing Rev function. This conclusion is supported by
the determination that both drugs block the nuclear
export of genomic HIV-1 RNA to the cytoplasm.
Testing confirmed that these compounds suppress
HIV-1 expression in T cells at doses below those previously used in humans for tumour chemotherapy.
Together, our observations demonstrate that small
molecules can be used to inhibit HIV-1 replication
by altering another avenue of viral RNA processing,
offering the potential for the development of novel
therapeutics for controlling this disease.
INTRODUCTION
The development of highly active anti-retroviral therapies
to suppress HIV-1 replication and prevent progression to
AIDS has saved countless lives in both the developed and

the developing worlds. However, none of the drug combinations in use today provide a cure for this infection,
and all necessitate strict adherence to treatment schedules
if viral suppression is to be maintained (1,2). In addition,
multiple studies have documented the ability of HIV-1 to
acquire resistance to drugs in current use and the subsequent transmission of resistant strains of HIV-1 between
individuals (3–8). With continued use of anti-retroviral
therapies in more diverse populations, it can be
anticipated that strains of HIV-1 resistant to current
drug cocktails will evolve and become more common
(9). As a result, efforts must continue in the search for
new anti-HIV compounds that have mechanisms of
action distinct from the drugs currently in use.
Current HIV-1 therapeutics target all the enzymatic
functions encoded by the virus (reverse transcriptase,
protease, and integrase) as well as entry into the cell
(10,11). Consequently, novel strategies, to complement
the existing therapies, should target other aspects of the
virus life cycle. One such step is the processing and expression of HIV-1 RNA. Following integration, a 9-kb transcript is generated from the provirus that is subsequently
processed into >40 mRNAs to allow expression of all of
the viral structural, enzymatic, and regulatory proteins
(12–15). The unspliced (US) 9-kb viral RNA can be used
to express the HIV-1 Gag and Gagpol proteins, undergo a
single splicing event to produce the singly spliced (SS)
class of viral RNAs encoding Vif, Vpr, Vpu and Env, or
go through multiple splicing events to generate multiple
spliced (MS) RNAs that produce Tat, Rev and Nef.
Balancing the extent of HIV-1 RNA splicing is critical
to replication ﬁtness because too little splicing results in
loss of Tat and Rev, which are essential for enhancing the
transcription of the provirus and inducing expression of
the viral structural proteins, respectively. In contrast,
oversplicing of the viral RNA will impair the production
of HIV-1 structural proteins (Gag, Gagpol, and Env),
which are essential to new virus assembly (16–18).
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MATERIALS AND METHODS
For more detailed experimental procedures,
Supplementary Materials and Methods.

obtained from J. Dougherty (UMDNJ-RWJMS, NJ)
(27). With this cell line, latent provirus expression was
induced by addition of 1.8 mM phorbol 12-myristate 13acetate (PMA) after similar treatment procedures
described earlier in the text. After 24 h, cells were harvested for RNA/protein or XTT assay of cell viability
(Sigma-Aldrich, #TOX2), whereas media or cells were
lysed with 1% TX-100 for analysis of HIV-1 gene expression by p24CA ELISA described later in the text. For experiments using infected patient samples, peripheral blood
mononuclear cells (PBMCs) were ﬁrst depleted of CD8+T
cells using Dynabeads CD8 (Invitrogen, #111.47D) as
outlined by manufacturer. Depletion was conﬁrmed by
ﬂow cytometry analysis of CD8 and CD3 surface
markers. Remaining cells were then activated by treatment
with anti-CD3 and anti-CD28 antibodies (Bio Legend
#302914 and 317304, respectively; 1 mg/ml of each) as
well as 50 U/ml of IL-2 (BD Pharmingen #554603) in
the presence or absence of indicated drugs. Media
(0.5 ml) were collected every 3–4 days and replaced with
fresh media (0.5 ml) containing 20 U/ml of IL-2 and fresh
drug. Effect of compounds on cell viability was monitored
in parallel by XTT assay and expressed relative to control
(DMSO)-treated cells. HIV-1 growth in cultures was
monitored by p24CA ELISA of cell supernatants.
Analysis of HIV-1 expression
To monitor HIV-1 gene expression, cell culture supernatants or cell lysates were assayed for production of
Gag protein by a HIV-1 p24CA antigen capture assay kit
(AIDS & Cancer Virus Program, NCI-Frederick,
Frederick, MD, USA). For further analysis of HIV-1
protein expression, western blots were performed on cell
lysates. The antibodies and conditions used for Tat, antitubulin and isotype-speciﬁc HRP-conjugated antibodies
were used as described (24). Additional antibodies used
include anti-p24 from hybridoma 183 and mouse antigp120 from hybridoma 902 (AIDS Research and
Reference Reagent Program, Division of AIDS, NIAID,
NIH), mouse anti-Rev (Abcam, #ab85529) and rabbit
anti-GAPDH (Sigma, #9545). Generally, Western
Lightning-ECL (Perkin-Elmer, #NEL101) or Western
Lightning Plus-ECL (#NEL105) for anti-Rev, -Tat and
-gp120 blots was used. Signals were acquired by a
ChemiDoc MP with Image Lab software (Bio-Rad) or
exposed onto autoradiography ﬁlm.
Effect of compounds on RNA processing and transport

see

Screening of splice modulator compounds/drugs for effects
on HIV-1 RNA processing
Screens were performed using the HeLa rtTA-HIV-Mls
cell line containing a doxycycline (Dox)-inducible Tet-On
HIV-1 LAI strain provirus (25,26) as described in our
previous study (24). Compounds tested were obtained
from the ChemBridge Online Chemical Store (www.
hit2lead.com). Additional tests of compounds were performed using the SupT1-based cell line, 24ST1NELSG,

RNA was extracted from cells, reverse transcribed and
HIV-1 mRNA levels quantitated by qRT-PCR as
described (24). The effect of drugs on HIV-1 splice site
usage within the 2-kb MS RNA class was analysed by
RT-PCR of cDNA as previously described (24). For
analysis of alternative splicing of cellular RNAs, the inclusion levels of 157 alternatively spliced exons and splice
sites located in 96 alternatively spliced regions of 85 genes
(Supplementary Dataset S1) was assayed by medium
throughput RT-PCR. This set of events had been previously suggested to be linked to cell transformation and
was available for use in the laboratory. Labelled PCR
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Because of the need to balance the processing of viral RNA,
HIV-1 has evolved various strategies to regulate the extent
of splicing as well as the use of speciﬁc splice sites, i.e. the
presence of suboptimal splicing signals, exon splicing silencers, and exon splicing enhancers (12,15). However, the
virus is completely reliant on host splicing factors to
carry out the processing of its RNA. Multiple studies
during the past decade have demonstrated how changes
in abundance of various hnRNP and SR proteins, known
regulators of RNA splicing, can dramatically alter the
balance between HIV-1 US, SS, and MS RNAs by
changing the frequency of speciﬁc splice site use, resulting
in signiﬁcant impairment of virus replication (12,15,19–21).
The parallel determination that activity of the SR proteins
can be modulated by multiple kinases (SRPK1, SRPK2,
CLK1, CLK2, CLK3, and CLK4) (22,23) opens up the
possibility that modulation of kinase activity could
induce changes in HIV-1 RNA splicing and, subsequently,
replication. Recent experiments by our group have conﬁrmed this hypothesis by demonstrating that overexpression of speciﬁc CLKs results in suppression of viral
Gag and Env expression, a response that can be replicated
with the use of the small molecule inhibitor, chlorhexidine,
a known modulator of CLK function (24).
A recent high-throughput screen of chemical libraries for
modulators of SMN2 alternative RNA splicing identiﬁed
several active compounds (Perciﬁeld et al., submitted for
publication). To assess whether any of these compounds
also altered HIV-1 RNA processing, we tested a subset of
these active compounds. In this report, we present data that
8-azaguanine (8-Aza) and 2-[2-(5-nitro-2-thienyl)vinyl]quinoline (designated 5350150) induce a marked decrease in
HIV-1 Gag and Env expression, but via distinct mechanisms. The 8-Aza treatment altered viral RNA abundance
and use of speciﬁc splice sites. In contrast, 5350150 had a
more limited effect on HIV-1 RNA processing. Neither
compound was found to result in marked changes in the
levels of Rev, but both blocked cytoplasmic accumulation of
HIV-1 US RNA. Further analysis revealed that these compounds alter Rev subcellular distribution and transport,
suggesting that they also impair Rev function. Together,
these ﬁndings highlight the potential use of small molecules
to modulate HIV-1 RNA processing to inhibit viral replication, validating the targeting of this stage of the virus life
cycle as a potential therapeutic strategy.
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Effect of compounds on HIV-1 Rev subcellular
distribution
HeLa Rev cells (stably expressing HIV-1 Rev) were treated
with compounds as indicated. For studies using import or
export inhibitors, leptomycin B (LB) was added at 20 ng/ml
for 2 h before ﬁxing, whereas cells treated with 4 mg/ml
actinomycin D were incubated for 2 h before ﬁxation.
Slides were processed as detailed in the Supplementary
Materials and Methods and probed by primary rabbit
antibody against Rev, detected by either FITC- or Cy5labelled
donkey
anti-rabbit
antibody
(Jackson
Laboratories), and imaged at 630 or 400 magniﬁcation
by epiﬂuorescence microscopy. To examine the effects of
drugs on the subcellular localization of host nuclear
proteins, ﬁxed cells were stained with mouse anti-hnRNP
A1 (from Benoit Chabot), anti-SRp20 (Invitrogen,
# 334200), or anti-SC35 (Sigma, # S4045) antibody.
Statistical analysis
Data were analysed by Microsoft Excel and expressed as
means ± standard error of the mean (SEM). Differences
between two groups of data [compound/drug treatment
versus DMSO (+Dox) control or compound/drug treatment versus DMSO (+HIV) control] were compared by
two-tailed Student’s t-test. Statistical signiﬁcance of
results is indicated on graphs as follows: P < 0.05, *,
P < 0.01, ** and P < 0.001, ***, unless otherwise indicated.
RESULTS
8-Aza and 5350150 suppress HIV-1 structural protein
expression
To evaluate a panel of RNA splicing modulators for their
effect on HIV-1 RNA processing, we performed initial
analyses using the HeLa rtTA-HIV-Mls cell line
described previously (24). In brief, the cell line contains
an HIV-1 LAI provirus in which the RT and IN reading
frames had been deleted, the Nef region replaced with the
rtTA activator, and multiple TetO operators inserted into
the U3 region (25,26). These modiﬁcations render expression of the provirus dependent on addition of doxycycline
(Dox) to the media. Cells were treated for 4 h with each
compound (Figure 1A) at the doses indicated, and then
viral expression was induced by Dox addition for 20 h.

Media and cells were harvested at 24 h and analysed for
alterations in HIV-1 gene expression. Analysis of cell
media from various treatments for HIV-1 p24 Gag
protein (Figure 1B) revealed that addition of either 8-Aza
or 5350150 resulted in substantial reduction in Gag expression, comparable with that seen in the absence of Dox, with
maximum suppression requiring 20–45 mM 8-Aza or
1–2 mM 5350150 (Figure 1C and D). Parallel assays of
the effects of the compounds on cell viability (XTT assay,
Figure 1C and D) determined that neither 8-Aza nor
5350150 resulted in marked reductions in viability for the
time frame or drug concentrations used.
To probe the basis of the response seen, the effects of
either compound on the expression of HIV-1 Gag, Env,
Tat, or Rev were analysed by western blot. As shown in
Figure 1E, western blots of cell lysates determined that
both 8-Aza and 5350150 reduced HIV-1 Env expression
to a similar extent as Gag. However, neither compound
had much effect on the expression of other HIV-1
proteins such as Rev and p16 Tat encoded by MS RNA
(Figure 1F) in contrast to another modulator of HIV-1
RNA processing, chlorhexidine (24). These ﬁndings
support the conclusion that general protein expression is
not affected by these compounds. Treatment with 8-Aza
caused depletion of p14 Tat, a Tat isoform encoded by
SS RNA that is dependent on Rev-mediated export, suggesting that at least one of these compounds may act by
impairing Rev function.
8-Aza dramatically alters HIV-1 RNA processing
Based on the effect of these compounds on HIV-1 gene
expression and recently reported modiﬁcation of RNA
splicing (Perciﬁeld et al., unpublished data), we
examined whether either compound altered HIV-1 RNA
accumulation or splice site selection. As indicated in
Figure 2A and B, qRT-PCR analyses determined that 8Aza treatment signiﬁcantly altered HIV-1 RNA accumulation (similar to chlorhexidine) (24). Treatment with this
compound reduced both US and SS viral RNA abundance
to 20% of control (+Dox) levels, whereas MS RNA accumulation was increased by 1.5-fold. In contrast,
5350150 treatment led to only modest changes, US RNA
being reduced to 60% of control, no effect on SS RNA
accumulation, and a 1.5-fold increase in MS RNA abundance. In addition, there were no signiﬁcant effects on the
overall RNA concentration or copies of the housekeeping
gene, actin (data not shown). In light of these alterations,
we also investigated whether either compound elicited any
changes in the frequency of splice site use. To this end,
RT-PCR was performed to amplify viral MS RNAs, and
the products were analysed by separation on denaturing
gels. As seen in Figure 2C–E, treatment with 5350150 had
little effect on the frequency of splice site usage within MS
viral RNAs. In contrast, 8-Aza induced a marked alteration in splice site usage, strongly promoting the generation of Nef1 product [generated by the joining of the ﬁrst
50 splice site of HIV (SD1) with the last 30 splice site (SA7)]
with a comparable reduction in Nef2 RNA. In addition,
there was a modest reduction in the level of Rev1/2 and
increase of Tat1 and Tat2 RNAs.
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products were denatured in formamide and quantiﬁed
using an ABI Prism capillary sequencer (Life
Technologies). The inclusion level of each exon was
calculated as the amount of transcripts carrying the alternative exon relative to the total amount of all transcripts
detected in the PCR reaction.
To assess the impact of the various compounds on HIV1 US RNA subcellular distribution, cells were treated with
compounds as outlined earlier, processed and probed with
StellarisTM FISH probes comprising of a mixture of 48
Quasar 570-labelled 20-mer oligonucleotides spanning
the HIV-1 Gag coding region as outlined by the manufacturer (Biosearch Technologies). Images were captured by a
Leica DMR epiﬂuorescence microscope at 630 
magniﬁcation.
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Figure 1. Identiﬁcation of 8-Aza and 5350150 as potent inhibitors of HIV-1 gene expression. HeLa rtTA-HIV-Mls cells were treated with (A)
indicated compounds (80 nM digoxin, 45 mM 8-Aza, and 2 mM 5350150) or DMSO (control) for 4 h before induction of viral gene expression with (+)
and without () Dox for 20 h. Equal concentrations of DMSO solvent were present in each treatment. (B) Cell culture supernatants were harvested
after compound treatments for analysis of HIV-1 Gag protein expression by p24CA ELISA. For information on the relative efﬁcacy of each
compound, dose–response curves of the inhibition of HIV-1 gene expression by (C) 8-Aza (0–45 mM) and (D) 5350150 (0–2 mM) were generated
(black diamonds). In parallel, the effect of compounds on cell viability was measured by XTT assay (gray circles). Data were averaged from n  5
independent experiments in (B) and n  4 in (C and D), displayed as a fraction relative to DMSO (+) control, error bars are SEM, and statistical
signiﬁcant changes [between compound treatments from DMSO (+) control] indicated by asterisks as detailed in ‘Materials and Methods’ section. In
addition, cells extracts were analysed by western blot with antibodies for (E) HIV-1 structural proteins, Gag and Env, and (F) viral regulatory
factors, Rev and Tat. Blots were probed with either anti-GAPDH or anti-tubulin antibody to conﬁrm equal loading of protein samples. Data are
representative of n  3 experiments in (E) and n  6 in (F). Lanes were cropped and assembled from the same blots.
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Figure 2. Effect of 8-Aza and 5350150 on HIV-1 and host RNA processing. The effects of 8-Aza or 5350150 on HIV-1 mRNA levels were assessed
by qRT-PCR (as described in ‘Materials and Methods’ section) of HeLa rtTA-HIV-Mls cells treated with 45 mM 8-Aza, 2 mM 5350150 or DMSO
(control) for 24 h with doxycycline before harvest. (A) The position of the primers (arrow points) used in qRT-PCR. (B) Abundance of HIV-1
unspliced (US, gray), singly spliced (SS, white), and multiply spliced (MS, black) mRNAs are shown relative to DMSO (+) controls. The housekeeping gene b-actin served as an internal loading control for the normalization of these data. Shown are data averaged from  5 experiments, error
bars are SEM, and signiﬁcant changes from control indicated by asterisks as described in ‘Materials and Methods’ section. (C-E) Changes in HIV-1
splice site use were assayed by RT-PCR of the 2 kb, MS class of HIV-1 mRNA (as outlined in ‘Materials and Methods’ section). (C) The position of
(continued)
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Measuring the effect of 8-Aza and 5350150 on host cell
RNA processing

Effects of 8-Aza and 5350150 on HIV-1 expression in
CD4+ T cells
Having demonstrated the capacity of 8-Aza and 5350150 to
suppress HIV-1 gene expression in our experimental
system, we validated their anti-viral activity in a human
CD4+ T cell line (24ST1NLESG) containing an inducible
HIV-1 provirus (Figure 3A) (27). As shown in Figure 3B–C,
both 8-Aza and 5350150 resulted in a marked reduction in
HIV-1 Gag expression without signiﬁcant effects on cell
viability at all concentrations shown. Additional western
blots conﬁrmed that, although these compounds reduced
Gag expression, they had little to no effect on Tat or Rev
levels in this cell line (Supplementary Figure S2).
Subsequent analysis of the effect of the compounds on
viral RNA accumulation (Figure 3D) revealed that each
had effects similar to those seen in the HeLa rtTA-HIVMls cell line; 8-Aza reduced the level of both US and SS
RNAs by 80%, whereas 5350150 decreased only US RNA
levels with no or only moderate effects on SS and MS RNA
abundance. The similarity in effect of both 8-Aza and

Both 8-Aza and 5350150 alter Rev localization
Although the alteration in HIV-1 US, SS, and MS RNAs
induced by 8-Aza could account for the reduced expression of the corresponding proteins (Gag and Env), a
similar case cannot be made for 5350150. The loss of
both Gag and Env expression on addition of 5350150 suggested that it might impair Rev function. The ability of
Rev to shuttle between the nucleus and cytoplasm is
critical for its ability to export US and SS viral RNAs
to the cytoplasm and their subsequent translation
(28,29). Consequently, alterations in either Rev nuclear
import or export could reduce its function and be reﬂected
in changes in its subcellular distribution or localization of
Rev-dependent viral RNAs. As a test of this hypothesis,
the effect of 8-Aza or 5350150 on Rev subcellular distribution was examined by immunoﬂuorescence microscopy.
To monitor changes in Rev localization in response to
drugs, we used a HeLa Rev cell line that constitutively
expresses Rev alone at higher levels than the HeLa
rtTA-HIV-Mls cell line to better assess changes in Rev
activity. As previously reported and shown in Figure 5A,
Rev is predominately localized to the nucleus and, in particular, the nucleolus in the absence of any treatment
(DMSO) (30). However, on addition of actinomycin D
(Act. D), Rev accumulates in the cytoplasm (31). This
response can be reversed by leptomycin B (LB, an inhibitor of the Rev export mediator, Crm1) (32). Act. D acts to
invert the relative rates of Rev import into and export out
of the nucleus, resulting in export being the dominant
pathway. LB, which inhibits Rev export by inactivating
Crm1, induces nuclear accumulation of Rev by allowing
only import to occur. To assess whether either 8-Aza or

Figure 2. Continued
the primers (arrow points) used to amplify MS mRNA species. (D) Representative RT-PCR gel of the levels of each MS mRNA species (arrows)
from HeLa rtTA-HIV-Mls cells treated with doxycycline and 45 mM 8-Aza, 2 mM 5350150 or DMSO as performed in Figure 1. See Supplementary
Figure S1 for a description of the PCR products generated. (E) Graph summarizing the effects of 8-Aza (white), 5350150 (black), and control
treatments (gray) on the level of each MS mRNA species (x-axis) relative to the total HIV-1 MS mRNA (y-axis), displayed as percentage (%) of the
total HIV-1 MS RNA. Data were averaged from  6 experiments, error bars are SEM, and signiﬁcant differences from control indicated by asterisks
as described in ‘Materials and Methods’ section. (F and G) RNAs from treatments outlined earlier in the text were subsequently used to analyse for
changes in host RNA splicing. Primer pairs spanning host RNA alternative splicing event were used to amplify from cDNA and amplicons
quantitated following resolution by capillary electrophoresis. Shown is a comparison of the level of alternative exon inclusion following treatment
with (F) 5350150 or (G) 8-Aza relative to DMSO-treated cells. Values are the average of three independent trials, and events signiﬁcantly different
from control (DMSO) at P < 0.05 are indicated by open diamonds. The dotted line (grey) reﬂects the anticipated results if the drugs had no effect on
host RNA splicing. The solid line (black) is linear regression of the data with strength of the correlation indicated.
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The changes in HIV-1 RNA processing in response to
either 8-Aza or 5350150 raised the question as to
whether either compound had much broader effects on
RNA splicing. To address this point, we analysed for
changes in 90 known alternative splicing events on
addition of either compound (see Supplementary
Dataset S1 for the list of genes analysed and primers
used). Primer pairs spanning the alternative splicing
events were used to amplify cDNA prepared from mock
or treated cells and changes in exon inclusion assessed by
quantitation of the amplicons following separation by capillary eletrophoresis. As shown in Figure 2F (see
Supplementary Dataset S2 for values obtained for individual genes), comparison of the level of alternative spliced
products in the presence and absence of drug revealed few
signiﬁcant differences from control in the case of 5350150.
In contrast, treatment with 8-Aza was observed to induce
signiﬁcant alterations in a subset of alternative splicing
events (Figure 2G). The majority of the affected RNAs
showed reduced exon inclusion in response to this drug
but none to the same extent as seen for HIV-1 RNA.
Based on these ﬁndings, it can be concluded that neither
5350150 nor 8-Aza is acting through a general perturbation of the splicing process but rather are having selective
effects on a subset of host RNAs.

5350150 in two cell lines examined suggests that the
targets of these two compounds are conserved.
To validate our ﬁndings in a more relevant setting, the
ability of 8-Aza or 5350150 to suppress HIV-1 replication
was examined in the context of CD8-depleted PBMCs
obtained from treatment-naı̈ve HIV-infected patients.
Cells were incubated in the presence of lamivudine
(3-TC) (a reverse transcriptase inhibitor), 8-Aza or
5350150 and media harvested at various days after cell
activation. As shown in Figure 4A–C, both 8-Aza and
5350150 displayed signiﬁcant suppression of viral growth
at a dose of 1 mM. Subsequent dose response analysis
(Figure 4D and E) determined that optimal suppression
of HIV-1 growth was obtained at 10 mM of 8-Aza or
0.5 mM of 5350150.

Nucleic Acids Research, 2013, Vol. 41, No. 20 9477

Figure 3. Both 8-Aza and 5350150 inhibit HIV-1 expression in a CD4+
T cell line. Using a CD4+ T cell line (SupT1) stably transduced with an
HIV-1 provirus [(A) 24ST1NLESG], cells were treated with (B) 8-Aza
or (C) 5350150 at concentrations indicated, and HIV-1 provirus expression induced by addition of PMA after 4 h as detailed in ‘Materials and
Methods’ section. Equal concentrations of DMSO solvent were present
at each concentration tested. After 24 h, media were collected and the

Figure 3. Continued
levels of HIV-1 gene expression assessed by p24CA ELISA. Cell viability was also assessed in parallel by XTT assays. (D) Effect of 8-Aza and
5350150 on HIV-1 mRNA accumulation. Following treatment of cells
with DMSO, 10 mM 8-Aza or 7 mM 5350150, virus gene expression was
induced by addition of PMA. After 24 h, total RNA was extracted and
viral RNA abundance analysed by qRT-PCR as outlined in ‘Materials
and Methods’ section. Shown are data averaged from 3 independent
experiments, error bars are SEM and signiﬁcant changes from control
indicated by asterisks as described in ‘Materials and Methods’ section.
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5350150 also affects Rev transport, cells were treated with
either compound overnight. As shown in Figure 5B,
addition of either 8-Aza or 5350150 induced Rev accumulation in the cytoplasm (similar to the effect on Act. D
treatment). Subsequent time course experiments
determined that 8-Aza induced a shift in Rev subcellular
distribution within 4 h, whereas the same effect required
16 h of treatment with 5350150 (Supplementary Figure
S3). To determine whether the effects of 8-Aza or 5350150
on Rev subcellular distribution reﬂected a general perturbation in nuclear protein distribution, we also examined for
changes in SC35 as well as known shuttling factors,
hnRNP A1 and SRp20 (33,34). As shown in Figure 5C
and D and Supplementary Figure S4, neither 8-Aza nor
5350150 induced any detectable alteration in distribution
of other nuclear or nuclear shuttling proteins examined,
suggesting that the responses seen for Rev are selective.
Changes in Rev localization could reﬂect changes in one
or both of the rates of Rev nuclear export or import. To
gain insight into which process is affected, we assessed the
ability of LB to induce nuclear accumulation of Rev in the
presence of compound (as described in Figure 5A, where
LB reversed the effects of Act. D-treated cells). Cells were
treated with either 8-Aza or 5350150 overnight to induce
Rev relocalization, and then treated with LB for several
hours before ﬁxation and analysis. As shown in Figure 5E
and Supplementary Figure S3C, LB treatment was successful in reversing the effect of 8-Aza and Act. D on
Rev subcellular distribution, inducing complete nuclear
accumulation of Rev. Thus, 8-Aza is not solely impeding
Rev nuclear import. In contrast, LB treatment only partially induced nuclear accumulation of Rev in the presence
of 5350150, indicative of reduced rate of Rev nuclear
import. The differences in response of 8-Aza and
5350150 to LB add further evidence that these compounds
function via distinct mechanisms.
To assess whether alterations in Rev localization
induced by either compound affected HIV-1 RNA transport, in situ hybridization for HIV-1 US RNA was performed. As shown in Figure 6, HIV-1 US RNA
(DMSO+Dox) is normally distributed throughout both
the nucleus and cytoplasm; the discrete spots in the
nucleus reﬂecting accumulation at the sites of provirus
transcription. However, treatment with either 5350150 or
8-Aza resulted in the detection of HIV-1 US RNA only in
discrete foci in the nucleus with little signal in the cytoplasm, consistent with a block in the nuclear export of
this RNA.
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DISCUSSION
The development of highly active anti-retroviral therapies
has saved countless lives because of its ability to suppress
virus replication, offering the prospect of a normal
lifespan for those infected with HIV-1. However, it is
not a cure (2). Further complicating treatment is the
capacity of HIV-1 to rapidly adapt to both immune and
drug pressure. Such evolution is evident in the transmission of HIV-1 strains resistant to one or more drugs
(1,4,5,7). To ensure that patients continue to have a

range of treatment options, efforts should be directed
towards the development of novel therapeutics that complement the action of existing drugs. To this end, we have
been exploring the use of small molecular modulators of
alternative RNA splicing to suppress HIV-1 replication.
In support of the viability of this approach, recent work
by another group has used indole derivatives to successfully inhibit HIV-1 RNA processing (21,35). In this report,
we demonstrate that both 8-Aza and 5350150 are potent
suppressors of HIV-1 gene expression, each operating by
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Figure 4. Suppression of HIV-1 replication in chronically infected PBMCs by 8-Aza and 5350150. CD8-depleted PBMCs from chronically HIV-1infected patients were activated by treatment with anti-CD3 and anti-CD28 antibodies to induce HIV-1 growth in the culture. Cells were treated with
3-TC, 8-Aza, or 5350150 (triangles), or control (DMSO, diamonds). Equal concentrations of DMSO solvent were present at each concentration of
compound/drug tested. Media were harvested at multiple times points (0-21 days) to assess virus replication by p24CA ELISA of Gag. Shown (A, B,
C) are the viral growth curves using 5 nM 3-TC, 1 mM 8-Aza or 1 mM 5350150, and (D, E) the dose response effects of the indicated drugs after 14
days in culture. Results shown are derived from assays performed on four different patient samples. Effect of drugs on cell viability (Cell Viab.) was
also tested by XTT assay and results expressed relative to DMSO-treated cells (grey circles). All error bars are SEM and statistical signiﬁcance
indicated by asterisks as detailed in ‘Materials and Methods’ section.
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Figure 5. Both 8-Aza and 5350150 alter the subcellular distribution of HIV-1 Rev but not nuclear proteins of the host cell. HeLa Rev cells stably
expressing HIV-1 Rev were (A) control treated (DMSO) or incubated with 4 mg/ml of Act. D with (+) or without LB for 2 h or (B) treated with
compounds overnight with 45 mM 8-Aza or 2 mM 5350150 as described in Figure 1. After ﬁxation and permeabilization, localization of Rev was
detected by immunoﬂuorescence using a rabbit anti-Rev antibody followed by either a FITC- or Cy5-conjugated anti-rabbit IgG antibody. In
parallel, cells were stained with antibodies for (C) hnRNP A1 or (D) SRp20 as detailed in ‘Materials and Methods’ section. Shown are representative
images (gray scale) from three independent trials. Cells were stained with DAPI to allow imaging of the nuclei. Magniﬁcation 400. (E) To determine
whether 8-Aza or 5350150 were altering Rev localization by affecting Rev import, HeLa Rev cells were treated with DMSO, 2 h with Act. D (as a
control that induces Rev cytoplasmic accumulation) or overnight with either 45 mM 8-Aza or 2 mM 5350150, and then left untreated or treated with
LB (+LB) for 2 h before ﬁxation. Rev distribution was assessed in individual cells by immunoﬂuorescent staining using a rabbit anti-Rev antibody as
detailed in ‘Materials and Methods’ section. Individual cells were scored as having predominately nuclear (N > C, white), whole cell (N = C, grey) or
predominately cytoplasmic (N < C, black) patterns of Rev distribution. Shown are data averaged from three independent experiments, error bars are
SEM and signiﬁcant changes from control indicated by asterisks as described in ‘Materials and Methods’ section. Representative images of the
distribution patterns observed are provided in Supplementary Figure S3C.
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different mechanisms and distinct from that previously
documented for chlorhexidine (24).
In the 1950s, 8-Aza was tested in humans as a
chemotherapeutic agent for the treatment of leukaemia
at doses between 200 and 1000 mg (0.25–1.3 mM).
Although some anti-tumour responses were observed, undesirable reactions at these doses limited its therapeutic
use (36,37). Early studies in HeLa cells indicated only
minimal reduction in cell growth rates at doses of
<40 mM 8-Aza (38). At doses of 300 mM, there was not
only a small (10%) reduction in RNA synthesis but also
a 50% decrease in total protein production in these cells
(38). These observations were consistent with 8-Aza predominately affecting translation (39), in particular initiation of translation, as conﬁrmed in subsequent studies
(40). On the other hand, parallel analysis of 8-Aza in

two in vitro translation systems (where protein production
was not dependent on RNA synthesis) failed to show any
change in protein synthesis, supporting the conclusion
that 8-Aza does not act directly on protein synthesis but
rather acts by altering the mRNA template (41,42). In
addition, other studies of this anti-metabolite conﬁrmed
that it was incorporated in RNA but had little to no effect
on ribosomal RNA processing (43), suggesting that it was
acting at the level of mRNA. More recent studies have
identiﬁed additional effects of 8-Aza, including selective
changes in CD26 expression (44) and Von Hippel–
Lindau protein stability (45). Our study of this
compound expands its range of effects. The lack of any
alteration in Rev or p16 Tat levels in the presence of 8-Aza
indicates that the concentration required to suppress
HIV-1 structural protein expression has limited effect on
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Figure 6. 8-Aza and 5350150 inhibit the transport of HIV-1 US RNA to the cytoplasm. To assess the effect of compound treatments on the
subcellular distribution of HIV-1 genomic US RNA, HeLa rtTA-HIV-Mls cells were treated overnight with DMSO (DMSO+Dox), 40 mM 8Aza+Dox or 2 mM 5350150 (150+Dox) for 4 h before induction of viral gene expression with Dox for 20 h as described in Figure 1. Cells were
subsequently ﬁxed and processed for in situ hybridization of HIV-1 US RNA as detailed in ‘Materials and Methods’ section. Shown are representative distribution patterns observed from each treatment. Cells were stained with DAPI to detect nuclei (left), HIV-1 US RNA was detected in the
Cy3 channel (middle) and images were merged in colour (right). Patterns shown for each treatment are representative of n  4 independent
experiments.
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total protein synthesis. Rather, at 45 uM, 8-Aza induced
signiﬁcant alterations in viral RNA splicing as well as a
block in viral RNA export because of a shift in Rev
subcellular distribution.
In the case of splicing, treatment with 8-Aza resulted in
a signiﬁcant reduction in accumulation of the incompletely spliced (US and SS) viral RNAs with a slight
increase in MS viral RNA levels, consistent with induction
of oversplicing or a reduced stability of the incompletely
spliced viral RNAs. In addition, we detected a shift in the

pattern of splice site usage within the viral MS RNAs with
a dramatic increase in the generation of Nef1 RNA, corresponding to the joining of the ﬁrst 50 ss of HIV-1 (SD1)
to the last 30 ss (SA7), and a reduction in Nef2 RNA levels.
Analysis of the effect of 8-Aza on host RNA splicing
revealed some perturbations, but only to a limited
number of the splicing events analysed and none to the
same extent as observed for HIV-1. In light of the known
incorporation of 8-Aza into RNA, it may be acting to
alter recognition of splicing regulatory sequences by host
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Figure 7. 8-Aza and 5350150 inhibit HIV-1 replication by altering viral RNA processing. This diagram outlines the stages of RNA processing during
the HIV-1 life cycle. This study demonstrates that 8-Aza and 5350150 are potent inhibitors of HIV-1 replication that perturb viral RNA processing, a
stage of the virus life cycle not targeted by current anti-retroviral therapies. 8-Aza and 5350150 inhibit the virus by altering speciﬁc pre-mRNA
splicing events under the control/inﬂuence of the host. This includes (i) inducing oversplicing of HIV-1 pre-mRNA (depicted by an increasingly
yellow arrow), which reduces both US and SS mRNA levels (with the exception of 5350150 on SS mRNA), and (ii) altering the localization of HIV-1
Rev, resulting in sequestration of incompletely spliced (US and SS) RNAs to the cell nucleus. Both of these mechanisms lead to a reduction in US
and SS viral mRNAs available for translation, perturbing the synthesis of a subset of HIV-1 regulatory and accessory factors as well as structural
proteins/enzymes necessary for new virion assembly and infection. This study conﬁrms that small molecule inhibitors that alter viral RNA processing
can potently inhibit HIV-1 replication, signifying the potential of directing novel therapeutics to this stage for control of this disease.
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Analysis of structural variants of 5350150 that retain or
lose activity will be of critical importance in further
deﬁning its mechanism of action.
Although the documented toxicity of 8-Aza may
preclude its direct use for the suppression of HIV-1 replication in humans, the capacity of both small molecule
inhibitors to suppress expression from integrated HIV-1
provirus in multiple systems serves as proof that this stage
of the virus life cycle can be effectively targeted by such
agents. The distinct effects of 8-Aza and 5350150, but a
similar result on viral protein expression (loss of HIV-1
Gag and Env), highlight the fact that there are multiple
ways of achieving a post-transcriptional block to HIV-1
gene expression. In addition, as our understanding of their
mode of action increases (in particular, the host factors
being affected), we will be able to reﬁne our approach to
enhance the activity towards the protein targets of interest
while minimizing off target effects. Targeting this stage of
the HIV-1 life cycle has the potential to greatly synergize
with existing therapeutics, providing a more robust barrier
to the evolution of resistance, or serve as a second-line
treatment regimen in cases when ﬁrst-line therapies are
unsuccessful.
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